St. Jude Medical Announces FDA Approvals of Current ICD and Promote CRT-D Heart Failure Devices (RedNova)
St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) approval of its newest devices for treating patients with potentially lethal heart arrhythmias and heart failure.

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis (News-Medical-Net)
Abbott has announced it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and juvenile idiopathic arthritis (JIA) in the European Union (EU).